LONDON – Europe's largest small-molecule drug discovery services specialist, Evotec SE, is moving into biologics discovery and manufacturing via the acquisition of Just Biotherapeutics Inc., of Seattle. Evotec is paying $60 million in cash up front, with a further $30 million to follow, mainly in sales-related milestones, to acquire the 4-year-old company.